A New Strategy for Barrett’s Cancer Improves Survival and Reduces Recurrence
A major retrospective study in gastroenterology has demonstrated a significant improvement in oncological outcomes by prioritizing endoscopic submucosal dissection (ESD) over endoscopic mucosal resection (EMR) for larger Barrett’s esophagus cancers. The research, published in *Gut*, compared two treatment eras across multiple centers. In the more recent period, where ESD was routinely used for suspected cancers larger than 15 mm, the rate of complete basal resection (R0) surged to over 91%, a substantial increase from the historical rate. Most critically, for deeper T1b cancers, this shift led to a tripling of curative resection rates, a more than halving of recurrence, and a marked improvement in two-year cancer-free survival compared to EMR, all without increasing adverse event rates.
Study Significance: For critical care and ICU professionals managing complex post-procedural patients, this evidence supports a definitive shift in endoscopic practice that minimizes the need for salvage surgery and its associated critical care burden. Adopting a universal ESD-first approach for larger lesions directly impacts patient trajectories by reducing cancer recurrence and improving survival metrics, which can decrease long-term ICU admissions related to surgical complications or advanced disease. This study provides a clear, data-driven protocol update that enhances precision medicine in gastrointestinal oncology.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
